Corbus Pharmaceutical
Corbus Prescription drugs Holdings could now not be a hashish inventory within the conventional sense, however its origins hold it inside the orbit of life-science names as soon as grouped below the medical-cannabis banner.
Based in 2014, the corporate initially drew consideration for lenabasum, an artificial cannabinoid developed to deal with inflammatory and fibrotic illnesses. As regulatory progress and funding alternatives in cannabis-derived therapeutics slowed, Corbus pivoted towards oncology and metabolic problems, whereas retaining scientific experience in cannabinoid and receptor-based pathways.
That legacy continues via CRB-913, a peripherally restricted CB1 inverse agonist in improvement for weight problems — a mechanism rooted in endocannabinoid system analysis.
Immediately, Corbus is positioning itself as a clinical-stage oncology and weight problems firm with a diversified small-molecule and biologics pipeline. Its lead programme, CRB-701, is a next-generation antibody-drug conjugate (ADC) concentrating on Nectin-4, a tumour-associated antigen validated in urothelial and head-and-neck cancers. The corporate additionally develops CRB-601, an anti-integrin monoclonal antibody designed to dam TGFβ activation in most cancers cells, and CRB-913, its cannabinoid-based weight problems candidate.
Corbus’ shares have rallied sharply in current weeks following two key catalysts. On 16 September 2025, the US Meals and Drug Administration granted Quick Observe designation for CRB-701 in head-and-neck squamous cell carcinoma (HNSCC), marking its second such designation after metastatic cervical most cancers in 2024. The announcement signalled rising regulatory confidence within the programme’s scientific potential and triggered the beginning of a sustained share-price run.
Momentum continued after the corporate’s 14 October affirmation that it’s going to current up to date Part 1/2 information on the European Society for Medical Oncology (ESMO) 2025 Congress on 19 October. The dataset will embody 122 evaluable sufferers throughout a number of tumour varieties, and Corbus will host a key opinion chief occasion in Berlin to debate the outcomes. Investor anticipation forward of the presentation has fuelled additional positive factors, with the fill up roughly 60–70% month-to-date and greater than 150% since August.
With a money steadiness of $116.6m as of its Q2 2025 replace, offering runway into 2027, and a Reasonable Purchase analyst consensus with a mean 12-month goal of $45, Corbus has regained market visibility as one of many yr’s stronger-performing biotech names.
Stenocare
In Denmark, Stenocare delivered certainly one of its strongest quarters in current reminiscence, with buying and selling exercise surging amid renewed retail curiosity and enhancing sentiment within the Nordic hashish house.
Based on Nasdaq Nordic’s Q3 buying and selling statistics, Stenocare’s share value rose 120.5% through the quarter, climbing from DKK 0.54 on 30 June to DKK 1.20 on 30 September, whereas turnover reached DKK 24.1 m on 21.5 m shares traded. The corporate’s market capitalisation doubled to roughly DKK 50 m, marking its highest quarterly acquire since 2021.
Buying and selling velocity (complete turnover relative to common market capitalisation) accelerated sharply to 209.7%, in contrast with a broader First North Denmark benchmark of 40.7%, signalling an unusually excessive stage of liquidity for a small-cap inventory.
Retail participation was significantly pronounced as web brokers accounted for 49.5% of turnover and practically 56% of trades. Nordic banks contributed an additional 35.2% of worth traded, whereas international funding banks represented 15.2%.
The inventory hit a quarterly excessive of DKK 1.68 on 27 August and a low of DKK 0.40 on 7 July, reflecting vital intra-quarter volatility. The quantity-weighted common value (VWAP) stood at DKK 1.12, suggesting that the majority of shopping for occurred above prior assist ranges. Stenocare traded on 113.8% of obtainable market days, implying constant liquidity all through the quarter.
